Abstract 2062P
Background
PsyD is frequent in cancer pts and it negatively affects their treatment and quality of life. However, psychological screening is not extensively performed and few data about its impact are available. The aim of our study is to evaluate baseline PsyD in PC pts treated at our Institution and its correlation with clinicopathological features.
Methods
In the last year, we baseline evaluated PsyD of PC pts starting chemotherapy at our Institution, using the Distress Thermometer (DT) and Problem List (PL). The DT score was divided into three levels: no/minimal (0-3), moderate (4-6) and high (7-10) distress. PL was grouped into 6 categories (practical, physical, cognitive, spiritual/religious, emotional and family problems). Clinicopathological characteristics were collected and correlated with PsyD.
Results
A total of 86 PC pts were tested for baseline PsyD. The median age was 65 years, 63% were female, ECOG PS was > 1 in 56% of pts and 72% of pts had one or more comorbidities. The majority of pts (67%) received chemotherapy for metastatic disease. Regarding psychological screening, 31%, 29% and 40% of pts had no/minimal, moderate and high DT score, respectively. According to PL we observed: practical problems in 17% of patients, physical in 9%, cognitive in 42%, spiritual/religious in 9%, emotional in 16%, and family problems in 13% of patients. Regarding psycho-oncological care, 93% of pts received initial counseling, 63% intervention and follow-up. No significant association between DT score and PL groups with clinicopathological characteristics was observed.
Conclusions
Our mono-institutional analysis showed that the majority of PC pts receiving chemotherapy at our Institution presented a PsyD scored as moderate (29%) or high (40%) by DT at baseline. According to PL, the main problem concerned the cognitive sphere, specifically problems related to concentration and/or memory and self-perception. Additional analyses, including the impact of PsyD on treatment compliance, tolerability and prognosis are going.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Fondazione Policlinico Universitario Agostino Gemelli-IRCCS.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2045P - Patient Reported Outcome Measures (PROMs) capturing therapy adherence of cancer patients: A systematic literature review
Presenter: Luise Richter
Session: Poster session 06
2046P - The importance of communicating bad news in medical education
Presenter: Georgios Goumas
Session: Poster session 06
2047P - Neutrop: A descriptive, observational study for G-CSF prescription in daily practice
Presenter: Florian Scotté
Session: Poster session 06
2048P - Frequency and clinical relevance of drug-drug interactions with oxycodone among patients with cancer
Presenter: Lotte Hulskotte
Session: Poster session 06
2049P - Osimertinib-related muscle cramps as a common adverse event: A real-world data analysis in the post-approval setting
Presenter: Gisele Moreira
Session: Poster session 06
2050P - Integrating ayurveda herbs with standard of care for management of cancer or cancer treatment related anorexia
Presenter: Yogesh Bendale
Session: Poster session 06
2051P - E-PRO within comprehensive companion program for patients undergoing systemic cancer treatment to reduce emergency visits and inpatient admission in a Peruvian institution
Presenter: Patricia Rioja Viera
Session: Poster session 06
2052P - Adverse events in FLOT chemotherapy for locally advanced gastric cancer: An observational study of pre- and post-operative toxicity profiles
Presenter: Camila Oliveira
Session: Poster session 06
2053P - Dehospitalization through outpatient drug release in clinical pharmacy as a strategic cost-minimization action in a public oncology hospital in the Eastern Amazon: A quantitative analysis
Presenter: Kalysta Borges
Session: Poster session 06
2054P - Metastatic cancer patients hospitalized at initial diagnosis: When does rescue systemic therapy make sense? ONIRIS - A national, prospective study
Presenter: Colin Vercueil
Session: Poster session 06